Table 1 Patients’ baseline characteristics
| Male/female (%) | 240/374 (39/61) |
| Indication for IFX treatment (%) | |
| Luminal CD | 420 (68) |
| Fistulising CD | 170 (28) |
| Luminal CD and mainly extraintestinal manifestations | 24 (4) |
| Median (IQR) age at diagnosis (years) | 22.8 (17.8–29.9) |
| Median (IQR) age at first infusion (years) | 33.9 (24.9–43.3) |
| Median (IQR) duration of disease prior to first IFX (months) | 92.1 (28.2–188.9) |
| Median (IQR) patient’s follow-up of IFX treatment (months) | 55.3 (27.4–83.0) |
| Location of disease (%) | |
| Ileitis | 103 (16.8) |
| Colitis | 148 (24.1) |
| Ileocolitis | 326 (53.1) |
| Upper GIT | 37 (6.0) |
| Smokers (%) (n = 423) | 202 (47.8) |
| Concomitant medication at first IFX (%) | |
| Aminosalicylates | 202 (32.9) |
| Steroids | 198 (32.2) |
| 6-MP/AZA | 305 (49.7) |
| MTX | 58 (9.4) |
| Median (IQR) baseline CDAI (n = 362) | 253 (175–336) |
| Median (IQR) baseline CRP mg/l (n = 481) | 12.9 (5.0–32.4) |
| Previous major abdominal surgery (%) | 238/614 (38.8) |
-
A total of 614 patients with Crohn’s disease had been treated with infliximab between November 1994 and March 2007 at the University Hospital Leuven in Belgium.
-
AZA, azathioprine; CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; CRP, C-reactive protein; GIT, gastrointestinal tract; IFX, infliximab; IQR, interquartile range; 6-MP, 6-mercaptopurine; MTX, methotrexate.
